BIO Should Use Political Clout Carefully, Outgoing President Feldbaum Urges
Executive Summary
The biotechnology industry should reserve its political influence for the most fundamental policy issues, outgoing Biotechnology Industry Organization President Carl Feldbaum told the association's annual meeting in San Francisco June 8
You may also be interested in...
BIO Begins Search For New President; Feldbaum To Step Down By End Of Year
The Biotechnology Industry Organization will begin the process of selecting a new president at its Feb. 23 board meeting in New York
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials